Atlas Trials

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

Clinical trial NCT05088928 · UNKNOWN

Trial details

NCT number
NCT05088928
Sponsor
Scotmann Pharmaceuticals
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2022-03-01
Primary completion
2022-05-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.